Goldman Sachs Group Inc Eiger Bio Pharmaceuticals, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EIGR
# of Institutions
6Shares Held
748KCall Options Held
0Put Options Held
0-
Telemetry Investments, L.L.C. New York, NY345KShares$3.28 Million0.64% of portfolio
-
Act Capital Management, LLC Wayne, PA235KShares$2.23 Million2.44% of portfolio
-
Drw Securities, L.L.C. Chicago, IL120KShares$1.14 Million0.02% of portfolio
-
Dfpg Investments, LLC32.4KShares$308,0850.0% of portfolio
-
Zeke Capital Advisors, LLC Berwyn, PA13KShares$123,5000.0% of portfolio
About Eiger BioPharmaceuticals, Inc.
- Ticker EIGR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,966,800
- Market Cap $418M
- Description
- Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...